Literature DB >> 32101890

High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis.

Chen Yang1, Brian Shuch2, Harriet Kluger3, Peter A Humphrey1, Adebowale J Adeniran1.   

Abstract

Conflicting data have been published on the prognostic significance of histologic parameters in papillary renal cell carcinoma (PRCC). We conducted a comprehensive evaluation of clinical and histologic parameters in PRCC in nephrectomies and their impact on prognosis, with an emphasis on World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grade, tumor architecture (solid, micropapillary, and hobnail), and PRCC type. A total of 185 PRCC cases were evaluated, 117 (63.2%) type 1, 45 (24.3%) type 2, and 11 (5.9%) mixed type 1 and type 2. Using WHO/ISUP grading criteria, PRCCs were graded as follows: 6 (3.2%) grade 1; 116 (62.7%) grade 2; 61 (33.0%) grade 3; and 2 (1.1%) grade 4. The solid architecture was present in 3 cases (1.6%) and comprised 10%, 10%, and 30% of the tumor area. Micropapillary architecture was present in 10 cases (5.4%), ranging from 5% to 30% of the tumor (mean=11%; median=10%). Hobnail architecture was seen in 9 cases (4.9%), with mean percentage of 23% (median=15%; range: 5% to 50%) involvement of tumor area. Parameters associated with worse disease-free survival (DFS) and overall survival (OS) in the univariate analysis included WHO/ISUP grade, pathologic stage, tumor size, and solid, micropapillary, or hobnail architecture (P<0.05). The pathologic stage and WHO/ISUP grade were significantly associated with both DFS and OS in stepwise multivariate Cox regression analysis (P<0.05). In addition, micropapillary architecture and type 1 histology were linked with an adverse impact on OS (P<0.05). We found no difference in DFS (P=0.8237) and OS (P=0.8222) for type 1 versus type 2 PRCC in our patient cohort. In addition, we performed a meta-analysis with data from studies with reported hazard ratios (HRs) on PRCC type in relation to DFS and OS. We identified 5 studies that reported DFS and found no significant effect for type 2 PRCC (P=0.30; HR=1.43; 95% confidence interval: 0.73-2.80). We identified 7 studies that reported OS and found no significant association between type 2 PRCC and worse OS (P=0.41; HR: 1.21; 95% confidence interval: 0.77-1.91). Our findings suggest that high WHO/ISUP grade and unfavorable architecture (solid, micropapillary, or hobnail), rather than typing of PRCC, are associated with worse outcomes.

Entities:  

Mesh:

Year:  2020        PMID: 32101890     DOI: 10.1097/PAS.0000000000001455

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Papillary Renal Cell Carcinomas Demonstrating Micropapillary Features: An Investigation Into the Diagnostic and Prognostic Implications.

Authors:  Beatriz Caraballo; Maha Abdulla; Sunder Sham; Guang-Qian Xiao; Pamela Unger
Journal:  Cureus       Date:  2022-05-12

2.  Identification of a three-miRNA signature as a novel prognostic model for papillary renal cell carcinoma.

Authors:  Ge Li; Haifan Yang; Yong Cheng; Xin Zhao; Xu Li; Rui Jiang
Journal:  Cancer Cell Int       Date:  2020-07-16       Impact factor: 5.722

3.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Authors:  Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou
Journal:  Mod Pathol       Date:  2021-03-04       Impact factor: 8.209

4.  The Clinicopathological Features and Prognosis in Patients With Papillary Renal Cell Carcinoma: A Multicenter Retrospective Study in Chinese Population.

Authors:  Baoan Hong; Huimin Hou; Lingxiao Chen; Zhi Li; Zhipeng Zhang; Qiang Zhao; Xin Du; Yuan Li; Xiongjun Ye; Wanhai Xu; Ming Liu; Ning Zhang
Journal:  Front Oncol       Date:  2021-09-21       Impact factor: 6.244

5.  Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Shengwei Xiong; Weijie Zhu; Xinfei Li; Yanfei Yu; Kunlin Yang; Lei Zhang; Yue Mi; Xuesong Li; Liqun Zhou
Journal:  Transl Androl Urol       Date:  2021-08

6.  Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.

Authors:  Paari Murugan; Liwei Jia; Renzo G Dinatale; Melissa Assel; Nicole Benfante; Hikmat A Al-Ahmadie; Samson W Fine; Anuradha Gopalan; Judy Sarungbam; S Joseph Sirintrapun; A Ari Hakimi; Paul Russo; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter
Journal:  Mod Pathol       Date:  2021-12-23       Impact factor: 8.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.